Format

Send to

Choose Destination
See comment in PubMed Commons below
Orphanet J Rare Dis. 2017 Apr 17;12(1):61. doi: 10.1186/s13023-017-0614-4.

Opportunities for developing therapies for rare genetic diseases: focus on gain-of-function and allostery.

Author information

1
Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
2
Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. rbaltman@stanford.edu.
3
Department of Bioengineering, Stanford University School of Medicine, Stanford, CA, USA. rbaltman@stanford.edu.

Abstract

BACKGROUND:

Advances in next generation sequencing technologies have revolutionized our ability to discover the causes of rare genetic diseases. However, developing treatments for these diseases remains challenging. In fact, when we systematically analyze the US FDA orphan drug list, we find that only 8% of rare diseases have an FDA-designated drug. Our approach leverages three primary insights: first, diseases with gain-of-function mutations and late onset are more likely to have drug options; second, drugs are more often inhibitors than activators; and third, some disease-causing proteins can be rescued by allosteric activators in diseases due to loss-of-function mutations.

RESULTS:

We have developed a pipeline that combines natural language processing and human curation to mine promising targets for drug development from the Online Mendelian Inheritance in Man (OMIM) database. This pipeline targets diseases caused by well-characterized gain-of-function mutations or loss-of-function proteins with known allosteric activators. Applying this pipeline across thousands of rare genetic diseases, we discover 34 rare genetic diseases that are promising candidates for drug development.

CONCLUSION:

Our analysis has revealed uneven coverage of rare diseases in the current US FDA orphan drug space. Diseases with gain-of-function mutations or loss-of-function mutations and known allosteric activators should be prioritized for drug treatments.

KEYWORDS:

Allosteric; Drug discovery; Drug targets; Gain-of-function; Genetic diseases; Orphan drugs; Rare diseases

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center